title: Drug utilization review on a surgical intensive care unit.
abstract: Drug use reviews (DUR) provide information about drug prescription patterns. At the surgical intensive care unit (SICU) of the University Hospital Frankfurt/Main we recorded the indication related administration of blood products and pharmaceuticals (which were responsible for 60% of the total costs at the SICU in the year before) over a 4-month investigation period. Data were recorded and analyzed using a notebook-PC. 207 Patients were included, and recorded total expenditures came to $551,592. The 10 leading substances, represented by antibiotics and blood-products, caused more than 70% of total costs. The usage of these high-cost substances and the most expensive complications are identified and discussed. We concluded that DURs are useful for obtaining information about drug usage patterns and for identifying high cost drugs, which are of economic interest. Furthermore, the indications for the application of these substances can be identified. Our results suggest, that blood and blood-products should always be included in DURs. In our opinion, especially the usage of blood-products represents a field where considerable cost savings may be expected. As certain complications during the postoperative course (e.g. sepsis) may increase costs, they should be considered in the reimbursement negotiations between hospitals and health insurance.
authors: Department of Clinical Pharmacology, University Hospital Frankfurt/Main.
authors: J P
authors: JP
authors: Marschner
authors: P
authors: P
authors: Thürmann
authors: S
authors: S
authors: Harder
authors: N
authors: N
authors: Rietbrock
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000191:economics*; D001688:Biological Products / Q000191:economics*; D001779:Blood Coagulation Factors / Q000191:economics; D003362:Cost-Benefit Analysis; D003625:Data Collection; D016527:Drug Costs; D011307:Drug Prescriptions / Q000191:economics / Q000592:standards*; D017723:Drug Utilization Review; D005260:Female; D005858:Germany; D006801:Humans; D007075:Immunoglobulin M / Q000191:economics; D007362:Intensive Care Units / Q000191:economics* / Q000592:standards; D008297:Male; D008875:Middle Aged; D012709:Serum Albumin / Q000191:economics; D013503:Surgery Department, Hospital / Q000191:economics / Q000592:standards
chemical_list: D000900:Anti-Bacterial Agents; D001688:Biological Products; D001779:Blood Coagulation Factors; D007075:Immunoglobulin M; D012709:Serum Albumin; C025667:prothrombin complex concentrates